ALLO — Allogene Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1737287 ·
Last close
$0.74
Market Cap
$257.08M
52W High
$4.46
52W Low
$0.74
ADV30
9,919,924
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -54,793,000 | -50,369,000 | 511,320,000 | 29,270,000 | 118,768,000 |
| Jun 2026 | 4,640,000 | — | -46,920,000 | -42,677,000 | 550,091,000 | 38,626,000 | 113,916,000 |
| Mar 2026 | 0 | — | -46,092,000 | -42,607,000 | 395,958,000 | 30,309,000 | 117,083,000 |
| Dec 2025 | 0 | — | -42,404,000 | -38,810,000 | 415,905,000 | 51,688,000 | 123,363,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-102,196,000
Investing CF
$-131,599,000
Financing CF
$220,089,000
CapEx
$-446,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.67
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,095,993,000
Inventory
—
Receivables
—
ST Investments
$293,978,000
EBIT TTM
$-164,194,000
Pretax Income TTM
$-165,494,000
Interest Exp TTM
$1,300,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,640,000
EBITDA
$-179,216,992
Free Cash Flow
$-63,461,624
Enterprise Value
$361,378,784
Total Cash
$332,604,000
Total Debt
$79,009,000
Shares Out
345,490,881
Trailing EPS
$-0.61
Book Value
$1.27
ROE
-42.4%
ROA
-22.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -206,933,000 | -190,886,000 | 415,905,000 | 123,363,000 | 292,542,000 | -149,246,000 |
| Dec 2024 | 22,000 | -257,482,000 | -257,590,000 | 548,710,000 | 126,531,000 | 422,179,000 | -200,300,000 |
| Dec 2023 | 95,000 | -314,492,000 | -327,265,000 | 642,837,000 | 130,604,000 | 512,233,000 | -237,733,000 |
| Dec 2022 | 156,000 | -335,536,000 | -340,414,000 | 821,579,000 | 154,697,000 | 666,882,000 | -220,519,000 |
TTM Snapshot
Revenues TTM
$4,640,000
NetIncome TTM
$-165,494,000
OpCashFlow TTM
—
Assets (Latest)
$550,091,000
Forward EPS
$-0.62
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.70 · call volume: 12 · put volume: 100Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OCGN | Ocugen, Inc. | $256.75M | $0.76 | — |
| IPSC | Century Therapeutics, Inc. | $248.79M | $1.37 | — |
| SABS | SAB Biotherapeutics, Inc. | $265.76M | $2.95 | — |
| PLX | Protalix BioTherapeutics, Inc. | $242.84M | $2.88 | — |
| TRXB | TRex Bio, Inc. | $274.46M | $10.00 | — |
News headlines (Yahoo Finance, 1h cache)
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
2026-11-09 13:00 · Yahoo
Allogene (ALLO) Q3 2026 Earnings Call Transcript
2026-11-06 15:32 · Yahoo
Allogene Therapeutics Inc (ALLO) (Q3 2026) Earnings Call Highlights: Alpha 3 Momentum Builds as ...
2026-11-06 07:19 · Yahoo
Allogene Therapeutics Q3 Earnings Call Highlights
2026-11-06 00:14 · Yahoo
Allogene Therapeutics: Q3 Earnings Snapshot
2026-11-05 21:33 · Yahoo
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
2026-11-05 21:02 · Yahoo
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting
2026-11-03 13:00 · Yahoo
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
2026-10-29 12:30 · Yahoo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
2026-10-26 12:30 · Yahoo
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
2026-09-02 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.